Ten Reasons Why Neurologists Should Refer Patients With Alzheimer Dementia to Music Therapy.

IF 2.3 Q3 CLINICAL NEUROLOGY

Neurology. Clinical practice Pub Date : 2024-12-01 Epub Date: 2024-08-16 DOI:10.1212/CPJ.0000000000200357

Shauna H Yuan, Michael J Silverman, Andrea M Cevasco-Trotter, Sonya G Wang

{"title":"Ten Reasons Why Neurologists Should Refer Patients With Alzheimer Dementia to Music Therapy.","authors":"Shauna H Yuan, Michael J Silverman, Andrea M Cevasco-Trotter, Sonya G Wang","doi":"10.1212/CPJ.0000000000200357","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer dementia (AD) constitutes a major societal problem with devastating neuropsychiatric involvement. Pharmaceutical interventions carry a heightened risk of side effects; thus, nonpharmacological interventions such as music-based interventions (MBIs), including music therapy, are recommended.Recent findings: The 2023 Neurology release of the Music Based Intervention Toolkit for Brain Disorders of Aging showcased music's emerging role as an intervention to manage symptoms of various brain disorders while defining the building blocks of MBIs to guide research in the exploration of music's therapeutic potential.Implications for practice: This study extends beyond the research aspects of the MBI Toolkit to clinical applications by providing neurologists with a summary of MBIs, the MBI Toolkit, how board-certified music therapists (MT-BCs) administered music therapy is a unique MBI, and 10 reasons why they should make referrals to music therapy for their patients with AD.","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341083/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alzheimer dementia (AD) constitutes a major societal problem with devastating neuropsychiatric involvement. Pharmaceutical interventions carry a heightened risk of side effects; thus, nonpharmacological interventions such as music-based interventions (MBIs), including music therapy, are recommended.

Recent findings: The 2023 Neurology release of the Music Based Intervention Toolkit for Brain Disorders of Aging showcased music's emerging role as an intervention to manage symptoms of various brain disorders while defining the building blocks of MBIs to guide research in the exploration of music's therapeutic potential.

Implications for practice: This study extends beyond the research aspects of the MBI Toolkit to clinical applications by providing neurologists with a summary of MBIs, the MBI Toolkit, how board-certified music therapists (MT-BCs) administered music therapy is a unique MBI, and 10 reasons why they should make referrals to music therapy for their patients with AD.

查看原文本刊更多论文

神经科医生应让阿尔茨海默氏症痴呆患者接受音乐治疗的十个理由。

背景：阿尔茨海默氏痴呆症（AD）是一个重大的社会问题，涉及毁灭性的神经精神疾病。药物干预具有较高的副作用风险，因此建议采用非药物干预，如基于音乐的干预（MBI），包括音乐疗法：2023 年《神经病学》发布了《基于音乐的老龄化脑部疾病干预工具包》，展示了音乐作为一种干预手段在控制各种脑部疾病症状方面的新兴作用，同时定义了 MBI 的基本模块，以指导探索音乐治疗潜力的研究：本研究将MBI工具包的研究内容延伸至临床应用，为神经科医生提供了MBI概述、MBI工具包、经委员会认证的音乐治疗师（MT-BC）如何管理音乐疗法这一独特的MBI，以及他们应该为AD患者转诊音乐疗法的10个理由。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology. Clinical practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

0.00%

发文量

期刊介绍： Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.